Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave
In this GEN webinar, downstream process development and scale up manufacturing specialists will discuss practical strategies for building robust purification processes when the target molecule misbehaves. The post Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave appeared first on GEN - Genetic Engineering and Biotechnology News .
Downstream Processing: Purifying Complex Antibody Therapeutics When Target Molecules Misbehave
AstraZeneca's Dr. David Scherr, a senior scientist, recently discussed the challenges of purifying complex antibody therapeutics during a panel discussion. Scherr, who has been working on the Integrated Dynamic Bioprocessing (IDB) platform, shared insights into the difficulties encountered when target molecules behave unexpectedly during purification.
Avid Bioservices' Dr. Anupama Kante, a scientist in downstream process development, also contributed to the discussion. Kante highlighted the importance of a comprehensive approach to purification, encompassing biologics purification, formulation development, and analytical characterization. She emphasized the need to advance monoclonal antibodies and complex biologics from early development through process optimization.
Thermo Fisher Scientific's Dr. Sam Ruesing, a senior staff scientist, added his perspective on the topic. Ruesing underscored the significance of addressing misbehaving target molecules in downstream processing. He stressed the need for innovative solutions to ensure the successful purification of complex antibody therapeutics.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
